Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases

Nature Reviews Drug Discovery

Volumn 9, Issue 2, 2010, Pages 107-115

  Cao, Yihai ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANGIOGENESIS INHIBITOR; FUMAGILLOL CHLOROACETYLCARBAMATE; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; RECOMBINANT LEPTIN; THROMBOSPONDIN; VASCULOTROPIN A;

ADIPOCYTE; ADIPOSE TISSUE; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BROWN ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; COLD EXPOSURE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENERGY EXPENDITURE; FOOD INTAKE; HEMATOPOIETIC STEM CELL; HUMAN; HYPOXEMIA; INFLAMMATORY CELL; MESENCHYMAL STEM CELL; METABOLIC DISORDER; NEUROTOXICITY; NONHUMAN; NOTE; OBESITY; PRIORITY JOURNAL; PROADIPOCYTE; STROMA CELL; ULCER; VASCULAR ENDOTHELIUM; VASCULARIZATION; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE;

ADIPOSE TISSUE; ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-OBESITY AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; METABOLIC DISEASES; NEOVASCULARIZATION, PHYSIOLOGIC; OBESITY;

EID: 75849165542     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3055     Document Type: Note

References (136)

1. World Health Organization. Obesity and overweight fact sheet. The World Health Organization website [online] http://www.who.int/dietphysicalactivity/ media/ en/gsfs-obesity.pdf. 2009.
2. Cao, Y. Angiogenesis modulates adipogenesis and obesity. J. Clin. Invest. 11 7, 2362-2368 (2007).
3. Cooke, D. & Bloom, S. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nature Rev. Drug Discov. 5, 919-931 (2006).
4. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1, 27-31 (1995)
5. Lijnen, H. R. Angiogenesis and obesity. Cardiovasc. Res. 78, 286-293 (2008).
6. Cao, Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int. J. Biochem. Cell Biol. 33, 357-369 (2001).
7. Folkman, J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N. Engl. J. Med. 333, 1757-1763 (1995).
8. Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364 (1996).
9. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005).
10. Nyberg, P., Xie, L. & Kalluri, R. Endogenous inhibitors of angiogenesis. Cancer Res. 65, 3967-3979 (2005).
11. Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
12. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
13. Kerbel, R. S. Tumor angiogenesis. N. Engl. J. Med. 358, 2039-2049 (2008).
14. Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
15. Gragoudas, E. S., Adamis, A. P., Cunningham, E. T. Jr, Feinsod, M. & Guyer, D. R. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351, 2805-2816 (2004).
16. Steinbrook, R. The price of sight \-ranibizumab, bevacizumab, and the treatment of macular degeneration. N. Engl. J. Med. 355, 1409-1412 (2006).
17. Duh, E. & Aiello, L. P. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 48, 1899-1906 (1999).
18. Gariano, R. F. & Gardner, T. W. Retinal angiogenesis in development and disease. Nature 438, 960-966 (2005).
19. Feldmann, H. M., Golozoubova, V., Cannon, B. & Nedergaard, J. UCP1 ablation induces obesity and abolishes diet-induced thermogenesis in mice exempt from thermal stress by living at thermoneutrality. Cell Metab. 9, 203-209 (2009).
20. Lodhi, I. J. & Semenkovich, C. F. Why we should put clothes on mice. Cell Metab. 9, 111-112 (2009).
21. Xue, Y. et al. Hypoxia-independent angiogenesis in adipose tissues during cold acclimation. Cell Metab. 9, 99-109 (2009).
22. Crossno, J. T. Jr, Majka, S. M., Grazia, T., Gill, R. G. & Klemm, D. J. Rosiglitazone promotes development of a novel adipocyte population from bone marrow-derived circulating progenitor cells. J. Clin. Invest. 116, 3220-3228 (2006).
23. Tang, W. et al. White fat progenitor cells reside in the adipose vasculature. Science 322, 583-586 (2008).
24. Hotamisligil, G. S. Inflammation and metabolic disorders. Nature 444, 860-867 (2006).
25. Powell, K. Obesity: the two faces of fat. Nature 447, 525-527 (2007).
26. Cao, R., Brakenhielm, E., Wahlestedt, C., Thyberg, J. & Cao, Y. Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc. Natl Acad. Sci. USA 98, 6390-6395 (2001).
27. Kamba, T. et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am. J. Physiol. Heart Circ. Physiol. 290, H560-H576 (2006).
28. Friedman, J. M. & Halaas, J. L. Leptin and the regulation of body weight in mammals. Nature 395, 763-770 (1998).
29. Yamauchi, T. et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423, 762-769 (2003).
30. Jansson, P. A. Endothelial dysfunction in insulin resistance and type 2 diabetes. J. Intern. Med. 262, 173-183 (2007).
31. Bakker, W., Eringa, E. C., Sipkema, P. & van Hinsbergh, V. W. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell Tissue Res. 335, 165-189 (2009)
32. Goldberg, R. B. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J. Clin. Endocrinol. Metab. 94, 3171-3182 (2009).
33. Rutkowski, J. M., Davis, K. E. & Scherer, P. E. Mechanisms of obesity and related pathologies: the macro-and microcirculation of adipose tissue. FEBS J. 276, 5738-5746 (2009).
34. Sierra-Honigmann, M. R. et al. Biological action of leptin as an angiogenic factor. Science 281, 1683-1686 (1998).
35. Aleffi, S. et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 42, 1339-1348 (2005).
36. Dobson, D. E. et al. 1-Butyryl-glycerol: a novel angiogenesis factor secreted by differentiating adipocytes. Cell 61, 223-230 (1990).
37. Brakenhielm, E. et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc. Natl Acad. Sci. USA 101, 2476-2481 (2004).
38. Mahadev, K. et al. Adiponectin inhibits vascular endothelial growth factor-induced migration of human coronary artery endothelial cells. Cardiovasc. Res. 78, 376-384 (2008).
39. Scroyen, I., Jacobs, F., Cosemans, L., De Geest, B. & Lijnen, H. R. Effect of plasminogen activator inhibitor-1 on adipogenesis in vivo. Thromb. Haemost. 101, 388-393 (2009).
40. Wang, Y. et al. Adiponectin modulates the glycogen synthase kinase-3β/β-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res. 66, 11462-11470 (2006).
41. Voros, G. et al. Modulation of angiogenesis during adipose tissue development in murine models of obesity. Endocrinology 146, 4545-4554 (2005).
42. Landskroner-Eiger, S. et al. Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo. Clin. Cancer Res. 15, 3265-3276 (2009).
43. Ouchi, N. et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J. Biol. Chem. 279, 1304-1309 (2004). (Pubitemid 38082655)
44. de Fraipont, F., Nicholson, A. C., Feige, J. J. & Van Meir, E. G., Thrombospondins and tumor angiogenesis. Trends Mol. Med. 7, 401-407 (2001).
45. Hosogai, N. et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 56, 901-911 (2007).
46. Trayhurn, P., Wang, B. & Wood, I. S. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br. J. Nutr. 100, 227-235 (2008).
47. Bertolini, F., Shaked, Y., Mancuso, P. & Kerbel, R. S. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nature Rev. Cancer 6, 835-845 (2006).
48. Lyden, D. et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Med. 7, 1194-1201 (2001).
49. Shaked, Y. et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313, 1785-1787 (2006).
50. Takahashi, T. et al. Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nature Med. 5, 434-438 (1999). (Pubitemid 29180584)
51. Pittenger, M. F. & Martin, B. J. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ. Res. 95, 9-20 (2004).
52. Prockop, D. J. et al. Potential use of stem cells from bone marrow to repair the extracellular matrix and the central nervous system. Biochem. Soc. Trans. 28, 341-345 (2000).
53. Wu, Y., Chen, L., Scott, P. G. & Tredget, E. E. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 25, 2648-2659 (2007).
54. Meliga, E., Strem, B. M., Duckers, H. J. & Serruys, P. W. Adipose-derived cells. Cell Transplant 16, 963-970 (2007).
55. Valina, C. et al. Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction. Eur. Heart J. 28, 2667-2677 (2007).
56. Grenier, G. et al. Resident endothelial precursors in muscle, adipose, and dermis contribute to postnatal vasculogenesis. Stem Cells 25, 3101-3110 (2007).
57. Kahn, C. R. Medicine. Can we nip obesity in its vascular bud? Science 322, 542-543 (2008).
58. Timmons, J. A. et al. Myogenic gene expression signature establishes that brown and white adipocytes originate from distinct cell lineages. Proc. Natl Acad. Sci. USA 104, 4401-4406 (2007).
59. Tong, Q. et al. Function of GATA transcription factors in preadipocyte-adipocyte transition. Science 290, 134-138 (2000).
60. Seale, P. et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature 454, 961-967 (2008).
61. Brakenhielm, E. et al. Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circ. Res. 94, 1579-1588 (2004).
62. Rupnick, M. A. et al. Adipose tissue mass can be regulated through the vasculature. Proc. Natl Acad. Sci. USA 99, 10730-10735 (2002).
63. O'Reilly, M. S. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328 (1994).
64. O'Reilly, M. S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285 (1997).
65. Tam, J. et al. Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells. PLoS ONE 4, e4974 (2009).
66. Fukumura, D. et al. Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. Circ. Res. 93, e88-97 (2003).
67. Kim, Y. M. et al. Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732. J. Mol. Endocrinol. 38, 455-465 (2007).
68. Satchi-Fainaro, R. et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nature Med. 10, 255-261 (2004).
69. Cao, Y. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Adv. Cancer Res. 100, 113-131 (2008).
70. Cao, Y., Zhong, W. & Sun, Y. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Semin. Cancer Biol. 19, 338-343 (2009).
71. Kolonin, M. G., Saha, P. K., Chan, L., Pasqualini, R. & Arap, W. Reversal of obesity by targeted ablation of adipose tissue. Nature Med. 10, 625-632 (2004).
72. Piqueras, L. et al. Activation of PPARβ/δ induces endothelial cell proliferation and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 27, 63-69 (2007).
73. Gealekman, O. et al. Enhanced angiogenesis in obesity and in response to PPARg activators through adipocyte VEGF and ANGPTL4 production. Am. J. Physiol. Endocrinol. Metab. 295, E1056-E1064 (2008).
74. Demeulemeester, D., Collen, D. & Lijnen, H. R. Effect of matrix metalloproteinase inhibition on adipose tissue development. Biochem. Biophys. Res. Commun. 329, 105-110 (2005).
75. Chavey, C. et al. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J. Biol. Chem. 278, 11888-11896 (2003).
76. Lijnen, H. R. et al. Matrix metalloproteinase inhibition impairs adipose tissue development in mice. Arterioscler Thromb. Vasc. Biol. 22, 374-379 (2002).
77. Christiaens, V., Voros, G., Scroyen, I. & Lijnen, H. R. On the role of placental growth factor in murine adipogenesis. Thromb. Res. 120, 399-405 (2007).
78. Lijnen, H. R. et al. Impaired adipose tissue development in mice with inactivation of placental growth factor function. Diabetes 55, 2698-2704 (2006).
79. Ejaz, A., Wu, D., Kwan, P. & Meydani, M. Curcumin inhibits adipogenesis in 3T3-L1 adipocytes and angiogenesis and obesity in C57/BL mice. J. Nutr. 139, 919-925 (2009).
80. Shin, J. H., Shin, D. W. & Noh, M. Interleukin-17A inhibits adipocyte differentiation in human mesenchymal stem cells and regulates pro-inflammatory responses in adipocytes. Biochem. Pharmacol. 77, 1835-1844 (2009).
81. Hill, A. M. et al. Can EGCG reduce abdominal fat in obese subjects? J. Am. Coll. Nutr. 26, 396S-402S (2007).
82. Kao, Y. H., Chang, H. H., Lee, M. J. & Chen, C. L. Tea, obesity, and diabetes. Mol. Nutr. Food Res. 50, 188-210 (2006).
83. Lin, J., Della-Fera, M. A. & Baile, C. A. Green tea polyphenol epigallocatechin gallate inhibits adipogenesis and induces apoptosis in 3T3-L1 adipocytes. Obes. Res. 13, 982-990 (2005).
84. Klaus, S., Pultz, S., Thone-Reineke, C. & Wolfram, S. Epigallocatechin gallate attenuates diet-induced obesity in mice by decreasing energy absorption and increasing fat oxidation. Int. J. Obes. (Lond.) 29, 615-623 (2005).
85. Cao, Y. & Cao, R. Angiogenesis inhibited by drinking tea. Nature 398, 381 (1999).
86. Yamauchi, T. et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nature Med. 13, 332-339 (2007).
87. Seeley, R. J., D'Alessio, D. A. & Woods, S. C. Fat hormones pull their weight in the CNS. Nature Med. 10, 454-455 (2004).
88. Saltiel, A. R. You are what you secrete. Nature Med. 7, 887-888 (2001).
89. O'Rahilly, S. Life without leptin. Nature 392, 330-331 (1998).
90. Friedman, J. M. Obesity in the new millennium. Nature 404, 632-634 (2000).
91. Frederich, R. C. et al. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nature Med. 1, 1311-1314 (1995).
92. Licinio, J. et al. Human leptin levels are pulsatile and inversely related to pituitary-adrenal function. Nature Med. 3, 575-579 (1997).
93. Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666-2676 (2007).
94. Caputo, G. M., Cavanagh, P. R., Ulbrecht, J. S., Gibbons, G. W. & Karchmer, A. W. Assessment and management of foot disease in patients with diabetes. N. Engl. J. Med. 331, 854-860 (1994).
95. Cao, Y. Positive and negative modulation of angio-genesis by VEGFR1 ligands. Sci. Signal. 2, re1 (2009).
96. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932-936 (2005).
97. Ferrara, N. & Kerbel, R. S. Angiogenesis as a therapeutic target. Nature 438, 967-974 (2005).
98. Carmeliet, P. & Tessier-Lavigne, M. Common mechanisms of nerve and blood vessel wiring. Nature 436, 193-200 (2005).
99. Carmeliet, P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nature Med. 6, 1102-1103 (2000).
100. Celletti, F. L. et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nature Med. 7, 425-429 (2001).
101. Jinnin, M. et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nature Med. 14, 1236-1246 (2008).
102. Ware, J. A. To o many vessels? Not enough? The wrong kind? The VEGF debate continues. Nature Med. 7, 403-404 (2001).
103. Kopelman, P. G. Obesity as a medical problem. Nature 404, 635-643 (2000).
104. Couzin, J. Medicine. Bypassing medicine to treat diabetes. Science 320, 438-440 (2008).
105. Cappuzzo, F., Bartolini, S. & Crino, L. Emerging drugs for non-small cell lung cancer. Expert Opin. Emerg. Drugs 8, 179-192 (2003).
106. Mistry, T., Digby, J. E., Desai, K. M. & Randeva, H. S. Obesity and prostate cancer: a role for adipokines. Eur. Urol. 52, 46-53 (2007).
107. Rakic, J. M., Blaise, P. & Foidart, J. M. Pegaptanib and age-related macular degeneration. N. Engl J. Med. 352, 1720-1721 (2005); author reply 352, 1720-1721 (2005).
108. Brown, D. M. et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1432-1444 (2006).
109. Rosenfeld, P. J. et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1419-1431 (2006).
110. Margolis, D. J., Crombleholme, T. & Herlyn, M. Clinical protocol: Phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Repair Regen. 8, 480-493 (2000).
111. Josifova, T., Schneider, U., Henrich, P. B. & Schrader, W. Eye disorders in diabetes: potential drug targets. Infect. Disord. Drug Targets. 8, 70-75 (2008).
112. Rodriguez-Fontal, M., Alfaro, V., Kerrison, J. B. & Jablon, E. P. Ranibizumab for diabetic retinopathy. Curr. Diabetes Rev. 5, 47-51 (2009).
113. Simo, R. & Hernandez, C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 51, 1574-1580 (2008).
114. Balfour, J. A. B. & Noble, S. Becaplermin. BioDrugs 11, 359-364 (1999).
115. Ladin, D. Becaplermin gel (PDGF-BB) as topical wound therapy. Plastic Surgery Educational Foundation DATA Committee. Plast. Reconstr. Surg. 105, 1230-1231 (2000).
116. Steed, D. L. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers. Plast. Reconstr. Surg. 11 7, 143S-149S; discussion 150S-151S (2006).
117. Lazar, M. A. How obesity causes diabetes: not a tall tale. Science 307, 373-375 (2005).
118. Lehrke, M. & Lazar, M. A. The many faces of PPARg. Cell 123, 993-999 (2005).
119. Menghini, R. et al. Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology 136, 663-672 e4 (2009).
120. Fantuzzi, G. & Faggioni, R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J. Leukoc. Biol. 68, 437-446 (2000).
121. Cho, C. H. et al. Angiogenic role of LYVE-1-positive macrophages in adipose tissue. Circ. Res. 100, e47-57 (2007).
122. Kaipainen, A. et al. PPARa deficiency in inflammatory cells suppresses tumor growth. PLoS ONE 2, e260 (2007).
123. Arany, Z. et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α. Nature 451, 1008-1012 (2008).
124. Rophael, J. A. et al. Angiogenic growth factor synergism in a murine tissue engineering model of angiogenesis and adipogenesis. Am. J. Pathol. 171, 2048-2057 (2007).
125. Moon, M. H. et al. Human adipose tissue-derived mesenchymal stem cells improve postnatal neovascularization in a mouse model of hindlimb ischemia. Cell Physiol. Biochem. 17, 279-290 (2006).
126. Nakagami, H. et al. Adipose tissue-derived stromal cells as a novel option for regenerative cell therapy. J. Atheroscler Thromb. 13, 77-81 (2006).
127. Fraser, J. K., Wulur, I., Alfonso, Z. & Hedrick, M. H. Fat tissue: an underappreciated source of stem cells for biotechnology. Trends Biotechnol. 24, 150-154 (2006).
128. Kubis, N. et al. Vascular fate of adipose tissue-derived adult stromal cells in the ischemic murine brain: a combined imaging-histological study. Neuroimage 34, 1-11 (2007).
129. Lin, J., Lindsey, M. L., Zhu, B., Agrawal, C. M. & Bailey, S. R. Effects of surface-modified scaffolds on the growth and differentiation of mouse adipose-derived stromal cells. J. Tissue Eng. Regen. Med. 1, 211-217 (2007).
130. Lovren, F. et al. Visfatin (nicotinomide phosphoribosyl-transferase/pre-B cell colony-enhancing factor) activates eNOS via Akt and MAP kinases and improves endothelial function. Am. J. Physiol. Endocrinol. Metab. 7 Apr 2009 (doi:10.1152/ ajpendo.90780.2008).
131. Marcus, A. J., Coyne, T. M., Black, I. B. & Woodbury, D. Fate of amnion-derived stem cells transplanted to the fetal rat brain: migration, survival and differentiation. J. Cell. Mol. Med. 12, 1256-1264 (2008).
132. Suga, H. et al. Functional implications of CD34 expression in human adipose-derived stem/progenitor cells. Stem Cells Dev. 18, 1201-1210 (2009).
133. Traktuev, D. O. et al. A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. Circ. Res. 102, 77-85 (2008).
134. Enerback, S. et al. Mice lacking mitochondrial uncoupling protein are cold-sensitive but not obese. Nature 387, 90-94 (1997).
135. Wallberg-Henriksson, H. & Zierath, J. R. A new twist on brown fat metabolism. Cell 137, 22-24 (2009).
136. Kuo, L. E. et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nature Med. 13, 803-811 (2007).